Same Drug Class

Nivolumab vs Rituximab

Nivolumab vs Rituximab: Overview

This comparison examines the pharmacological differences between Nivolumab and Rituximab.

Mechanism of Action

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Rituximab: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

Pharmacokinetics

Half-life: Nivolumab — 27 days; Rituximab — 22 days.

Chemical Properties

Type: Nivolumab — Antibody; Rituximab — Antibody.